Related references
Note: Only part of the references are listed.Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study
Hannah Tharmalingam et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial
Alfonso Gomez-Iturriaga et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Prostate high dose -rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer
Zaid A. Siddiqui et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
HDR Brachytherapy at a Dose of 21 Gy in a Single Fraction for Patients with Low-Intermediate Risk Prostate Cancer: Initial Toxicity Outcomes
Daniel Krauss et al.
Brachytherapy (2019)
MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial
Yasir Alayed et al.
RADIOTHERAPY AND ONCOLOGY (2019)
High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results
Pedro J. Prada et al.
BRACHYTHERAPY (2018)
Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy
Lucas C. Mendez et al.
BRACHYTHERAPY (2018)
Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy
Daniel J. Krauss et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer
Peter Hoskin et al.
RADIOTHERAPY AND ONCOLOGY (2017)
High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer
Shyamal Patel et al.
BRACHYTHERAPY (2017)
High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results
Henrik Hauswald et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up
Yasuo Yoshioka et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results
Pedro J. Prada et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature
Berardino De Bari et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
High-dose-rate brachytherapy as monotherapy for prostate cancer
D. Jeffrey Demanes et al.
BRACHYTHERAPY (2014)
ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer
I-Chow Joe Hsu et al.
BRACHYTHERAPY (2014)
High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective
Yasuo Yoshioka et al.
JOURNAL OF CONTEMPORARY BRACHYTHERAPY (2014)
The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer
Yasuo Yoshioka et al.
JOURNAL OF RADIATION RESEARCH (2013)
Using Dose Homogeneity Index and Conformity Index to Evaluate Prostate High-dose-rate Plan Quality and Consistency
E. T. Cirino et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
High Dose Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
C. Leland Rogers et al.
JOURNAL OF UROLOGY (2012)
HIGH-DOSE-RATE MONOTHERAPY: SAFE AND EFFECTIVE BRACHYTHERAPY FOR PATIENTS WITH LOCALIZED PROSTATE CANCER
D. Jeffrey Demanes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies
William C. Huang et al.
JOURNAL OF UROLOGY (2007)
Share Paper
